$27.87
▼ $-0.57
(-2.00%)
Vol 36K
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$193.7M
ROE
58.2%
Margin
-2411.4%
D/E
0.00
Beta
0.62
52W
$6–$25
Wall Street Consensus
10 analysts · Apr 20263
Strong Buy
6
Buy
1
Hold
0
Sell
0
Strong Sell
90.0%
Buy Rating
Price Chart
Similar Stocks
XOMA
Xoma Royalty Corp
P/E 15.2
$329.3M
IRD
Opus Genetics Inc
$138.6M
XFOR
X4 Pharmaceuticals Inc
$349.7M
NGNE
Neurogene Inc
$319.1M
FBRX
Forte Biosciences Inc
$341.6M
GLSI
Greenwich Lifesciences Inc
$291.1M
PALI
Palisade Bio Inc
$350.2M
CLYM
Climb Bio Inc
$272.7M
RZLT
Rezolute Inc
$218.8M
OVID
Ovid Therapeutics Inc
$116.1M
Earnings
Beat rate: 25.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Sep 2025 | $-1.16 | $-8.36 | $-7.20 |
| Jun 2025 | $-1.13 | $2.55 | +$3.68 |
| Mar 2025 | $-1.82 | $-7.43 | $-5.61 |
| Dec 2024 | $-1.37 | $-9.10 | $-7.73 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 58.2% | -921.2% | 58.2% | 58.2% | 58.2% | 58.2% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | 4043.3% | -484.9% | -132.3% | -132.3% | -2411.4% | -2411.4% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 16.41 | 16.38 | 16.41 | 16.41 | 13.15 | 13.15 |
Key Ratios
ROA (TTM)
-96.6%
P/S (TTM)
53.75
P/B
0.5
EPS (TTM)
$-19.76
CF/Share
$-1.11
52W High
$24.94
52W Low
$5.90
$5.90
52-Week Range
$24.94
How does SRZN compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
SRZN valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
53.8
▲
318%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
0.5
▼
79%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
SRZN profitability vs Biotechnology peers
ROE
58.2%
▲
187%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-2411.4%
▼
741%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-96.6%
▼
107%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
SRZN financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
13.2
▲
196%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.6
▼
36%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
SRZN fundamentals radar
SRZN
Peer median
Industry
SRZN profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
SRZN vs peers: key metrics
Latest News
No related news yet